Leerink Partners Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $127

Benzinga Newsdesk www.benzinga.com Negative 94.0%

Neg 94% Neu 0% Pos 0%

Leerink Partners analyst Daina Graybosch downgrades Gilead Sciences (NASDAQ:GILD) from Outperform to Market Perform and lowers the price target from $146 to $127.